You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

CLINICAL TRIALS PROFILE FOR BRIMONIDINE TARTRATE AND TIMOLOL MALEATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Brimonidine Tartrate And Timolol Maleate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00435058 ↗ Visual Function Changes After Intraocular Pressure Reduction Completed University of Sao Paulo N/A 2005-09-01 During the glaucomatous disease process, subpopulations of cells may be dead, damaged or healthy. Visual function changes could be observed due to a recovering of the suffering ganglion cells after the intraocular pressure reduction. This study aims at evaluating the correlation between intraocular pressure reduction and visual function changes in glaucoma patients after using antiglaucoma medications.
NCT00698945 ↗ Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed Bp Consulting, Inc Phase 4 2008-06-01 To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP). To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine Tartrate 0.2% BID as adjunctive therapy in adults with uncontrolled IOP's (determined by P.I. based on target pressures) currently treated with Latanoprost 0.05% in the study eye(s).
NCT00811564 ↗ An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects Completed Allergan Phase 4 2008-12-01 A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects
NCT00811850 ↗ Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow Completed Allergan Phase 4 2008-12-01 A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.
NCT01284166 ↗ Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Withdrawn Allergan Phase 3 2013-07-01 This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol maleate combination therapy.
NCT01987752 ↗ Safety and Efficacy of Combigan® Ophthalmic Solution in Korea Completed Allergan 2009-01-01 This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Combigan® (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta blockers treated as per standard of care in clinical practice.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brimonidine Tartrate And Timolol Maleate

Condition Name

Condition Name for Brimonidine Tartrate And Timolol Maleate
Intervention Trials
Glaucoma 4
Ocular Hypertension 4
Glaucoma, Open-Angle 1
Open-Angle Glaucoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Brimonidine Tartrate And Timolol Maleate
Intervention Trials
Glaucoma 5
Ocular Hypertension 4
Hypertension 3
Glaucoma, Open-Angle 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Brimonidine Tartrate And Timolol Maleate

Trials by Country

Trials by Country for Brimonidine Tartrate And Timolol Maleate
Location Trials
United States 3
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Brimonidine Tartrate And Timolol Maleate
Location Trials
Indiana 1
New York 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Brimonidine Tartrate And Timolol Maleate

Clinical Trial Phase

Clinical Trial Phase for Brimonidine Tartrate And Timolol Maleate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Brimonidine Tartrate And Timolol Maleate
Clinical Trial Phase Trials
Completed 5
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Brimonidine Tartrate And Timolol Maleate

Sponsor Name

Sponsor Name for Brimonidine Tartrate And Timolol Maleate
Sponsor Trials
Allergan 4
University of Sao Paulo 1
Bp Consulting, Inc 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Brimonidine Tartrate And Timolol Maleate
Sponsor Trials
Industry 4
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Brimonidine Tartrate and Timolol Maleate: A Comprehensive Overview of Clinical Trials, Market Analysis, and Projections

Introduction

Brimonidine tartrate and timolol maleate is a fixed combination ophthalmic solution used primarily for the treatment of glaucoma and ocular hypertension. This article delves into the clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Efficacy

FDA Approval and Clinical Studies

The FDA approved the fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% (Combigan, Allergan) in October 2007. This approval was based on several key clinical trials, including two identically designed, 12-month, double-masked studies. These trials involved 1,159 patients and measured intraocular pressure (IOP) at various times during follow-up visits. The results showed that the fixed combination reduced IOP by 4.4 to 7.6 mm Hg (up to 33%) across all visits, providing an additional 1 to 2 mm Hg decrease in IOP compared to timolol alone and 1 to 3 mm Hg compared to brimonidine alone[1].

Comparative Studies

A prospective, multicenter, randomized, double-masked trial compared the clinical success rates and quality of life impact of brimonidine 0.2% with timolol 0.5% in newly diagnosed patients. The study found that both treatments had similar clinical success rates (71% for brimonidine and 70% for timolol), with a mean IOP reduction of 6.5 mm Hg. Quality of life assessments using the SF-36 Health Survey and Glaucoma Disability Index questionnaires showed minimal differences between the two treatments[3].

Ocular Surface Health

Recent clinical trials have also focused on the impact of brimonidine/timolol on ocular surface health. For instance, a Phase 4 study (NCT06078592) compared the efficacy and ocular surface disease associated with this fixed combination, highlighting its safety and efficacy profile[4].

Mechanism of Action

Brimonidine tartrate and timolol maleate work through different mechanisms to reduce IOP. Brimonidine is an alpha-2 adrenergic agonist (ADRA2), which decreases aqueous humor production and increases its outflow. Timolol, on the other hand, is a beta-adrenergic antagonist (β-adrenoceptors), which primarily reduces aqueous humor production. The combination of these two mechanisms provides a synergistic effect, leading to a more significant reduction in IOP[2].

Market Analysis

Market Size and Sales

The market for brimonidine tartrate and timolol maleate ophthalmic solution is substantial. As of February 2023, the U.S. sales for this product were approximately $392 million over the preceding 12 months, according to IQVIA data. This indicates a strong demand for this treatment in managing glaucoma and ocular hypertension[5].

Generic Equivalents

The market has seen the introduction of generic equivalents, such as the one launched by Upsher-Smith Laboratories in partnership with RAFARM UK. This generic version is an AB-rated equivalent to the branded product Combigan, offering patients a more affordable option without compromising on efficacy and safety[5].

Competitive Landscape

The ophthalmic market for glaucoma treatments is competitive, with several other medications available. However, the fixed combination of brimonidine and timolol has carved out a niche due to its dual mechanism of action and proven efficacy in clinical trials. The presence of generic options further expands the market reach, making the treatment more accessible to a broader patient population.

Projections and Future Outlook

Market Growth

Given the increasing prevalence of glaucoma and ocular hypertension, the demand for effective treatments like brimonidine tartrate and timolol maleate is expected to grow. The introduction of generic versions is likely to drive market expansion by making the treatment more affordable and widely available.

Regulatory Approvals

The drug has already received approvals in key markets, including the United States and China. Continued regulatory approvals in other countries will further expand its global reach and contribute to market growth[2].

Research and Development

Ongoing research and development, particularly in the area of ocular surface health, will continue to enhance the profile of this drug. Innovations in formulation and delivery systems could also improve patient compliance and outcomes.

Quality of Life and Patient Compliance

Clinical Success and Quality of Life

Studies have shown that brimonidine tartrate and timolol maleate not only reduce IOP effectively but also have a minimal impact on quality of life. This is crucial for long-term patient compliance, as treatments that do not significantly affect daily life are more likely to be adhered to[3].

Patient Adherence

The fixed combination of brimonidine and timolol, administered twice daily, simplifies the treatment regimen compared to using separate medications. This simplicity can boost patient adherence, which is a critical factor in the effective management of glaucoma and ocular hypertension[1].

Side Effects and Safety Profile

Common Side Effects

While generally well-tolerated, common side effects include ocular pruritus, conjunctival hyperemia, and dry mouth. Serious side effects are rare but can include allergic reactions and systemic effects due to the beta-blocker component[5].

Safety in Clinical Trials

Clinical trials have demonstrated a favorable safety profile for the fixed combination. The trials highlighted that the side effects were manageable and did not significantly differ from those associated with the individual components[1].

Key Takeaways

  • Efficacy: Brimonidine tartrate and timolol maleate significantly reduce IOP, with clinical trials showing reductions of 4.4 to 7.6 mm Hg.
  • Market Size: The U.S. market for this product was approximately $392 million over 12 months as of February 2023.
  • Generic Options: The availability of generic equivalents expands market access and affordability.
  • Regulatory Approvals: Approved in the U.S. and China, with potential for further global approvals.
  • Quality of Life: Minimal impact on quality of life, enhancing patient compliance.
  • Safety Profile: Generally well-tolerated with a favorable safety profile in clinical trials.

FAQs

What is the primary indication for brimonidine tartrate and timolol maleate?

The primary indication is for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

How does the fixed combination of brimonidine and timolol work?

Brimonidine acts as an alpha-2 adrenergic agonist, reducing aqueous humor production and increasing its outflow, while timolol acts as a beta-adrenergic antagonist, primarily reducing aqueous humor production.

What are the common side effects of brimonidine tartrate and timolol maleate?

Common side effects include ocular pruritus, conjunctival hyperemia, and dry mouth.

Has the drug received regulatory approvals globally?

Yes, it has been approved in the United States and China, with ongoing efforts for approvals in other countries.

Are there generic versions of brimonidine tartrate and timolol maleate available?

Yes, generic equivalents have been launched, such as the one by Upsher-Smith Laboratories in partnership with RAFARM UK.

How does the fixed combination impact patient compliance?

The twice-daily administration simplifies the treatment regimen, potentially boosting patient adherence compared to using separate medications.

Sources

  1. FDA approval of brimonidine/timolol fixed combination may boost adherence. Ophthalmology Times.
  2. A Comprehensive Review of brimonidine tartrate/timolol maleate's R&D innovations. Synapse.
  3. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5%. PubMed.
  4. Brimonidine Tartrate/Timolol Maleate - Drug Targets, Indications. Synapse.
  5. Upsher-Smith Expands Ophthalmic Portfolio with Launch of Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution. Upsher-Smith.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.